On 2 July 2025, Sunshine Biopharma announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched Niopeg®, biosimilar to Amgen’s Neulasta® (pegfilgrastim) in Canada. Niopeg® was approved by Health Canada in April 2024 in pre-filled syringe of 6mg/0.6 ml.
The first pegfilgrastim biosimilar approved in Canada was Apotex’s Lapegla® in June 2018. Shortly after, Mylan/Biocon’s Fulphila® (pegfilgrastim) was approved in the US (June 2018) and Accord Healthcare’s Pelgraz (pegfilgrastim) was approved in the EU (September 2018).